GH Research PLC
GHRSNasdaqHealthcare · Pharmaceutical Preparations · L2 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2025-02Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects
- Phase 1Not Yet Recruitingreadout ~2026-05Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Lynx1 Capital Management LpPassive (13G)May 18, 2026
- Terwey Theis HPassive (13G)Nov 14, 2025
- Ra Capital Management, L.P.Passive (13G)Aug 14, 2025
- Fmr LlcPassive (13G)Aug 6, 2025
- Rtw Investments, LpPassive (13G)May 15, 2025
- Biotechnology Value Fund L PPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.1M | 12.4 | -2.4% |
| Apr 30, 2026 | 2.1M | 5.8 | -0.2% |
| Apr 15, 2026 | 2.2M | 20.6 | -2.9% |
| Mar 31, 2026 | 2.2M | 12.6 | -15.2% |
| Mar 13, 2026 | 2.6M | 9.4 | -3.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.